Agios Pharmaceuticals (AGIO) Share-based Compensation (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Share-based Compensation data on file, last reported at $15.9 million in Q2 2026.

• Quarterly Share-based Compensation rose 8.5% year-over-year to $15.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $58.0 million (up 20.55% YoY) and the FY2025 annual result came in at $52.6 million, up 22.65% from the prior year.
• Share-based Compensation advanced to $15.9 million in Q2 2026, from $15.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $15.9 million in Q2 2026 to a low of $9.1 million in Q3 2023.
• A 5-year average of $12.3 million and a median of $11.5 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 34.63% — and 2026, when it soared 36.82%.
• Tracing AGIO's Share-based Compensation over 5 years: stood at $11.5 million in 2022, then rose by 20.49% to $13.8 million in 2023, then decreased by 21.07% to $10.9 million in 2024, then climbed by 29.54% to $14.1 million in 2025, then climbed by 12.86% to $15.9 million in 2026.
• The last three Share-based Compensation figures came in at $15.9 million (Q2 2026), $15.5 million (Q1 2026), and $14.1 million (Q4 2025), per Business Quant data.